ResMed Inc. (ASX: RMD) shares have hit a 52-week low, but the valuation, earnings growth, and sleep health opportunity look ...

Medical device company ResMed (NYSE:RMD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ...

Thank you, Sally. Before we get into the details discussing our results for the quarter, I am sure all of you have had an opportunity to see our press release and our announcement that Brett will be ...

Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.

According to the release, ResMed delivered an 11% (8% in constant currency) increase in revenue to US$1.4 billion. This was ...

Jarden analyst Steven Wheen maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh today and set a price target of A$44.80. Claim 55% Of ...

ResMed posted stronger-than-expected Q1 2026 results with revenue of $1.43 billion and EPS of $2.86, driven by robust mask and device demand. The company announced CFO Brett Sandercock will retire in ...

RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools ...

Resmed has snapped up the California-based Noctrix Health, which makes a wearable, non-invasive device to tackle the annoying ...

Miners helped cushion the ASX 200, but weakness across banks, tech and healthcare kept the index under pressure. With NAB ...

Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales ...